Pharsight Scientists Will Present at First Joint U.S. National Modeling and
Simulation Meeting on March 11-12, 2008
MOUNTAIN VIEW, Calif., Mar. 4 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced its broad-based participation at the inaugural meeting of the American Conference on Pharmacometrics (ACoP). Pharsight scientists will make a total of 10 scientific contributions at this groundbreaking event, which will be held in Tucson, Arizona at the Westward Look Resort from March 9-12, 2008.
"This meeting illustrates the impact of pharmacometrics on the drug development process," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Pharmacometrics has been recognized by the FDA for improving new drug approval and labeling decisions, and academia and industry have responded by adding significant numbers to their staff in this area. We are delighted to recognize the significant growth of this profession by sponsoring its first, dedicated national conference."
Pharsight scientists will present on a range of modeling and simulation
subject areas, such as drug-disease modeling, clinical utility modeling,
and state-of-the-art tools and techniques, during two plenary conference
sessions and at three focused poster sessions, including:
-- Model-Based Literature Meta-Analysis: Virtues and Limitations. Dr.
Farkad Ezzet, senior scientist, Strategic Consulting Services, will
present as part of a dedicated conference session on altering disease
progression. Dr. Ezzet's presentation will outline how model-based
approaches for combining proprietary data on a specific compound with
literature data on its likely competitors can provide insight into
disease progression, effectiveness of current marketed therapies, and
tools for exploring the potential of new treatments.
-- Dosing Strategies of Drugs with Narrow Therapeutic Windows: A Simple
Approach to Determine Trade-off Between Efficacy and Toxicity. As part
of a poster session on pharmacometric tools and techniques, Dr. Samer
Mouksassi, associate scientist, Reporting and Analysis Services, will
describe research on how modeling and simulation methods have been
used to determine trade-offs between efficacy and toxicity in order to
design better dosing strategies.
"We look forward to sharing examples of strategic applications of modeling and simulation with industry colleagues and to discussing specific elements of our technology vision for the future of model-based drug development," added Mr. O'Connor.
A complete listing of Pharsight's ACoP presentations and poster contributions is available at http://www.pharsight.com/events/events_conferences.php.
The ACoP is organized and delivered by a cross-section of industry, academic and regulatory experts in the interdisciplinary science of pharmacometrics who also represent several regional U.S. modeling and simulation meetings and associations. Additional information about ACoP can be found at http://mosaicnj.com/acop/index.php.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved